MYLK promotes hepatocellular carcinoma progression through regulating cytoskeleton to enhance epithelial–mesenchymal transition
- 116 Downloads
Myosin light chain kinase (MYLK) is found to catalyze the phosphorylation of myosin light chains (MLC) and regulate invasion and metastasis in some malignancies. However, there is little knowledge on the role of MYLK in hepatocellular carcinoma (HCC), and no studies have been conducted to investigate the mechanisms underlying MYLK-mediated promotion of HCC invasion and metastasis until now. In this study, we investigated the expression of MYLK in 50 pairs of human HCC and adjacent liver specimens. High MYLK expression was significantly correlated with aggressive clinicopathological features including tumor encapsulation, microvascular invasion and metastasis. In vitro assays showed that shRNA-induced MYLK knockdown significantly inhibited the wound-healing ability of HCC cells and the ability to migrate and invade through Matrigel. We next uncovered that MYLK knockdown resulted in a reduction in the number of F-actin stress fibers, disorganization of F-actin architectures and morphological alterations of HCC cells. Phosphorylated MLC, rather than total MLC, was found to be markedly reduced in response to downregulation of MYLK expression, and MYLK-regulated actin cytoskeleton through phosphorylating MLC in HCC cells. In addition, Western blotting assay revealed downregulation of the epithelial marker E-cadherin and upregulation of mesenchymal markers Vimentin, N-cadherin and Snail. Taken together, our findings indicate that MYLK promotes HCC progression by altering cytoskeleton to enhance epithelial–mesenchymal transition (EMT).
KeywordsMyosin light chain kinase Hepatocellular carcinoma Cytoskeleton Invasion and metastasis Epithelial–mesenchymal transition
Myosin light chain kinase
Myosin light chains
Short hairpin RNAs
Quantitative real-time PCR
Sodium dodecyl sulfate polyacrylamide gel electrophoresis
This study was funded by the National Natural Science Foundation of China (Grant Number: ‘81301444’), the Special Fund of Fujian Provincial Department of Finance (Grant Number: ‘2014-1262’) and the Research Talent Training Program of Fujian Provincial Health and Family Planning Commission (Grant Number: ‘2017-ZQN-14’).
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
- 7.Cui WJ, Liu Y, Zhou XL, Wang FZ, Zhang XD, Ye LH. Myosin light chain kinase is responsible for high proliferative ability of breast cancer cells via anti-apoptosis involving p38 pathway. Acta Pharmacol Sin. 2010;31(6):725–32. https://doi.org/10.1038/aps.2010.56.CrossRefPubMedPubMedCentralGoogle Scholar
- 8.Tan X, Chen M. MYLK and MYL9 expression in non-small cell lung cancer identified by bioinformatics analysis of public expression data. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2014;35(12):12189–200. https://doi.org/10.1007/s13277-014-2527-3.CrossRefGoogle Scholar
- 11.Choi C, Kwon J, Lim S, Helfman DM. Integrin beta1, myosin light chain kinase and myosin IIA are required for activation of PI3 K-AKT signaling following MEK inhibition in metastatic triple negative breast cancer. Oncotarget. 2016;7(39):63466–87. https://doi.org/10.18632/oncotarget.11525.CrossRefPubMedPubMedCentralGoogle Scholar
- 13.Zuo L, Yang X, Lu M, Hu R, Zhu H, Zhang S, et al. All-Trans Retinoic Acid Inhibits Human Colorectal Cancer Cells RKO Migration via Downregulating Myosin Light Chain Kinase Expression through MAPK Signaling Pathway. Nutr Cancer. 2016;68(7):1225–33. https://doi.org/10.1080/01635581.2016.1216138.CrossRefPubMedGoogle Scholar
- 21.Wang B, Yan Y, Zhou J, Zhou Q, Gui S, Wang Y, Wang Y. A novel all-trans retinoid acid derivatives inhibits the migration of breast cancer cell lines MDA-MB-231 via myosin light chain kinase involving p38-MAPK pathway. Biomed Pharmacother. 2013;67(5):357–62. https://doi.org/10.1016/j.biopha.2013.03.016.CrossRefPubMedGoogle Scholar